Science News
from research organizations

Abaloparatide benefits a wide range of postmenopausal women with osteoporosis

Date:
September 19, 2016
Source:
Wiley
Summary:
A recent analysis of results from a randomized controlled clinical trial indicates that abaloparatide-SC, a novel therapy for osteoporosis, provides consistent protection against bone fractures in postmenopausal women with osteoporosis regardless of their baseline bone density, age, and previous history of fracture.<
Share:
FULL STORY

A recent analysis of results from a randomized controlled clinical trial indicates that abaloparatide-SC, a novel therapy for osteoporosis, provides consistent protection against bone fractures in postmenopausal women with osteoporosis regardless of their baseline bone density, age, and previous history of fracture.

Investigators in the ACTIVE trial previously found that that the drug reduces fractures and increases bone mineral density in postmenopausal women with osteoporosis. This latest analysis, which is published in the Journal of Bone and Mineral Research (published by the American Society for Bone and Mineral Research), evaluated whether these benefits were consistent across different levels of baseline risk.

"The landmark ACTIVE trial results show that abaloparatide-SC may provide substantial benefit for a broad range of postmenopausal women with osteoporosis," said lead author Dr. Felicia Cosman. "Approximately two million osteoporotic fractures occur annually in the U.S., which create physical and psychological burdens for affected women by diminishing their independence and quality of life. Anabolic therapy could provide more consistent potent and early benefits to patients and may be the most efficient way to achieve ultimate bone mineral density goals."


Story Source:

Materials provided by Wiley. Note: Content may be edited for style and length.


Journal Reference:

  1. Felicia Cosman, Gary Hattersley, Ming-yi Hu, Gregory C. Williams, Lorraine A. Fitzpatrick, Dennis M. Black. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women with Osteoporosis and Varying Baseline Risk Factors. Journal of Bone and Mineral Research, 2016; DOI: 10.1002/jbmr.2991

Cite This Page:

Wiley. "Abaloparatide benefits a wide range of postmenopausal women with osteoporosis." ScienceDaily. ScienceDaily, 19 September 2016. <www.sciencedaily.com/releases/2016/09/160919120757.htm>.
Wiley. (2016, September 19). Abaloparatide benefits a wide range of postmenopausal women with osteoporosis. ScienceDaily. Retrieved May 26, 2017 from www.sciencedaily.com/releases/2016/09/160919120757.htm
Wiley. "Abaloparatide benefits a wide range of postmenopausal women with osteoporosis." ScienceDaily. www.sciencedaily.com/releases/2016/09/160919120757.htm (accessed May 26, 2017).

RELATED STORIES